Angiocrine Bioscience is a startup based in the United States, most recent round Series B.
Based in the United States, Angiocrine Bioscience is a startup. Its most recent tracked round is Series B.
Angiocrine Bioscience is a clinical stage biotechnology company developing innovative cell therapies for hematologic diseases and cancer by targeting endothelial cells that regulate blood and lymphatic vessels.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.